For example, rituximab enhances NK cell responses against B-cell leukemias, ADCC can be triggered in neuroblastomas through anti-GD2 antibodies, and daratumumab (anti-CD38) is utilized in multiple myeloma [41,42,43,44,45]. Here, CD38 is linked to plasma cell myeloma.